GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (LSE:GSK) » Definitions » Institutional Ownership

GSK (LSE:GSK) Institutional Ownership : 40.72% (As of Apr. 27, 2024)


View and export this data going back to 1972. Start your Free Trial

What is GSK Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, GSK's institutional ownership is 40.72%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, GSK's Insider Ownership is 0.21%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, GSK's Float Percentage Of Total Shares Outstanding is 0.00%.


GSK Institutional Ownership Historical Data

The historical data trend for GSK's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Institutional Ownership Chart

GSK Historical Data

The historical data trend for GSK can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 39.02 38.98 39.13 39.68 39.40 39.30 39.94 40.40 41.18 40.72

GSK Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


GSK (LSE:GSK) Business Description

Address
980 Great West Road, Brentford, Middlesex, GBR, TW8 9GS
In the pharmaceutical industry, GSK ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.